Does Cigna Cover Prolia (Denosumab)?

How Cigna Classifies Prolia on Its Formulary

Cigna places Prolia on a specialty tier, typically Tier 4 or Tier 5, under most commercial PPO, HMO, and CDHP plan designs. Specialty-tier drugs carry the highest cost-sharing structure, which means members pay either a percentage of the drug's cost (coinsurance, often 20 to 33%) or a fixed specialty copay that can exceed $150 per dose depending on the benefit design.

Denosumab (Prolia) received FDA approval in June 2010 for postmenopausal women at high risk of fracture, with subsequent approvals for male osteoporosis, glucocorticoid-induced osteoporosis in adults at high fracture risk, and bone loss associated with hormone-ablation therapy [1]. Because the drug is administered by a healthcare provider as a subcutaneous injection every six months, many Cigna plans route it through the medical benefit (Part B equivalent) rather than the pharmacy benefit. The routing matters: medical-benefit claims use diagnosis codes (ICD-10 M81.0 for postmenopausal osteoporosis) and procedure codes (J0897 for denosumab injection) and may carry separate deductibles and out-of-pocket limits from prescription benefits [2].

Patients whose plans route Prolia through the pharmacy benefit will see it listed in the specialty tier of Cigna's standard drug formulary. Cigna publishes updated formulary documents each plan year; the most current version should be confirmed at the member portal or by calling the number on the insurance card. The American Society for Bone and Mineral Research notes that denosumab is an established standard of care for patients who cannot tolerate or have not adequately responded to oral bisphosphonates [3].

Prior Authorization Criteria Cigna Typically Applies

Prior authorization is required on virtually every Cigna commercial plan that covers Prolia. The authorization review is classified as moderate difficulty, meaning a well-documented chart will usually succeed, but incomplete submissions face high denial rates.

Cigna's internal medical policy for denosumab (policy IDs vary by plan year; confirm via Cigna's provider portal) generally requires the prescriber to demonstrate all of the following:

Diagnosis documentation. The member has a confirmed diagnosis of osteoporosis (T-score < -2.5 on dual-energy X-ray absorptiometry, or DXA), osteopenia with a FRAX 10-year major osteoporotic fracture probability of 20% or higher, or a history of low-trauma vertebral or hip fracture [4]. The National Osteoporosis Foundation guidelines, endorsed by the American Association of Clinical Endocrinologists, set these thresholds for initiating pharmacologic therapy [5].

Step-therapy completion. Cigna typically requires that the patient has tried and failed, or has a documented clinical contraindication to, at least one oral bisphosphonate such as alendronate 70 mg weekly or risedronate 35 mg weekly for a minimum of 3 to 6 months. Contraindications that may waive the step requirement include esophageal motility disorders, inability to sit upright for 30 minutes, severe renal impairment (estimated GFR <35 mL/min/1.73 m²), and intolerance documented by adverse-event notes [6].

Prescriber specialty. Some Cigna plan variants require the ordering clinician to be a rheumatologist, endocrinologist, or primary care physician with documented bone-health expertise. Others accept any licensed prescriber.

Quantity and frequency. Authorization covers 60 mg every 6 months (2 injections per 12-month authorization period). Requests outside this schedule require separate medical review.

Submitting a complete PA means including the DXA report with T-scores, the FRAX calculation printout, office notes documenting the bisphosphonate trial or contraindication, and a signed letter of medical necessity from the prescriber. The FREEDOM trial (N=7,868) demonstrated that denosumab reduced the risk of new vertebral fractures by 68% (RR 0.32; 95% CI 0.26, 0.41; P<0.001) compared to placebo over 36 months, which forms the core clinical justification cited in most PA letters [7].

Cigna targets a 72-hour turnaround for standard PA decisions and 24 hours for urgent (expedited) requests where a delay would seriously harm the patient's health. Providers can submit via Cigna's electronic prior-authorization portal, fax, or phone [8].

Step Therapy: What Cigna Requires Before Approving Prolia

Step therapy means the insurer requires a patient to try lower-cost alternatives before authorizing a more expensive drug. Cigna's step-therapy protocol for Prolia generally starts with generic oral bisphosphonates.

Alendronate sodium 70 mg tablets (generic, roughly $10, $30/month) and risedronate sodium 35 mg tablets are the most commonly required first steps. If a patient has already tried one of these for at least 3 months and experienced inadequate response (continued fracture, persistent bone loss on repeat DXA, or significant gastrointestinal adverse effects), the prescriber can document this in the PA request to move directly to Prolia [9].

Several clinical situations allow bypassing step therapy outright:

• Creatinine clearance <35 mL/min (bisphosphonates are relatively contraindicated due to accumulation risk)
• Active upper-GI disease (Barrett esophagus, achalasia, or active esophagitis)
• Documented hypocalcemia requiring active treatment (requires resolution before denosumab too, but bisphosphonates worsen it more acutely)
• Prior atypical femur fracture or osteonecrosis of the jaw attributed to bisphosphonate use

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "For women with very high fracture risk, anabolic agents (teriparatide, abaloparatide) or denosumab may be preferred over bisphosphonates as initial therapy" [10]. This language is useful in PA exception letters when the patient presents with a very high baseline fracture risk (T-score < -3.0 or prior hip or vertebral fracture).

What Happens After a Cigna Denial

Cigna denials for Prolia typically cite one of three reasons: (1) the step-therapy requirement was not met, (2) supporting clinical documentation was missing or incomplete, or (3) the requested indication is not covered under the member's specific benefit design. Each reason has a distinct rebuttal strategy.

Level 1 internal appeal. The prescriber or member must file within 180 days of receiving the denial notice. The appeal submission should add anything missing from the original PA: updated DXA results, FRAX scores, a more detailed letter of medical necessity, and any peer-reviewed references supporting use. The FREEDOM trial data [7] and the American College of Rheumatology's 2022 guideline on glucocorticoid-induced osteoporosis [11] are particularly persuasive for reviewers. Cigna must respond within 30 days for standard appeals and 72 hours for urgent appeals per federal requirements under the Affordable Care Act.

Level 2 internal appeal. If the Level 1 appeal is denied, a second internal review is available. This stage often involves a Cigna medical director review. Submitting a written opinion from the treating specialist (endocrinologist or rheumatologist) at this level significantly increases the chance of reversal.

External independent review. After exhausting both internal levels, the member or provider may request review by an independent review organization (IRO). IRO decisions are binding on Cigna under most state laws and ACA regulations. Studies have found that IROs overturn insurer denials in approximately 40% of specialty-drug cases [12]. The prescriber's letter for IRO review should cite specific guideline statements and the patient's individual clinical data side by side.

Peer-to-peer review. Before or during the appeal process, the prescriber can request a peer-to-peer call with Cigna's reviewing clinician. This call, typically 15 to 30 minutes, allows the treating physician to explain clinical reasoning directly. Peer-to-peer calls resolve a meaningful proportion of denials before the formal appeal is filed [13].

The HealthRX clinical team has developed a tiered PA and appeal checklist based on review of Cigna's publicly posted medical policies and member-reported outcomes across our patient cohort. The framework is outlined below and can be used by prescribers preparing documentation for any Cigna Prolia authorization:

Tier 1 (PA submission): DXA report with T-scores at spine and hip, FRAX 10-year probability, diagnosis ICD-10 codes, bisphosphonate trial or documented contraindication, letter of medical necessity with FREEDOM trial citation.

Tier 2 (Level 1 appeal add-ons): Updated clinical notes, specialist consult note, guideline quotes from Endocrine Society or ACR, patient-reported adverse effects from bisphosphonates with dates.

Tier 3 (IRO or Level 2): Full medical record excerpt, independent specialist written opinion, published pharmacoeconomic data on fracture-related hospitalization costs vs. Prolia cost, prior IRO precedent letters if available.

Using the Amgen Prolia Manufacturer Savings Card with Cigna

Amgen offers the Prolia SupportPlus program, which includes a co-pay savings card for commercially insured patients. The card may reduce out-of-pocket costs to as low as $0 per dose for eligible patients, with a maximum benefit of up to $3,500 per year (program terms subject to annual revision; verify at amgensupportplus.com) [14].

The savings card is available only to patients with commercial insurance coverage, which includes Cigna commercial plans. It cannot be used by patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded health program. Cigna members who have received prior authorization and have a high specialty copay or coinsurance should enroll in the Amgen program before the first injection date.

The Centers for Medicare and Medicaid Services has not restricted commercial co-pay card use by Cigna commercial plan members, but some employer-sponsored plans with health reimbursement arrangements (HRAs) may limit card stacking. Members should confirm with their plan administrator [15].

Cost Without Cigna Coverage

The wholesale acquisition cost of Prolia is approximately $1,500 per 60 mg injection, translating to roughly $3,000 annually for the two-injection schedule. This list price does not reflect rebates negotiated between Amgen and pharmacy benefit managers.

Patients without coverage or whose claims are denied pending appeal have three realistic options:

1. The Amgen patient assistance program (Amgen Safety Net Foundation) provides Prolia at no cost to uninsured or underinsured patients who meet income eligibility thresholds, generally at or below 500% of the federal poverty level [16].
2. Some hospital-affiliated infusion centers bill at rates significantly below list price when the drug is administered in a 340B-eligible facility.
3. Clinicians may consider switching to once-yearly intravenous zoledronic acid (5 mg, generic available) while the appeal is pending, provided the patient has no contraindications. The HORIZON Key Fracture Trial (N=7,765) demonstrated a 70% relative reduction in morphometric vertebral fractures with zoledronic acid vs. placebo over 3 years (P<0.001) [17], making it a defensible bridge therapy with Cigna reimbursement under pharmacy or medical benefit as a generic infusion.

Monitoring Requirements Cigna May Include in Authorization Conditions

Some Cigna prior-authorization approvals for Prolia include conditions on the authorization: the prescriber must confirm that serum calcium and vitamin D levels have been assessed and corrected before each injection, and that the patient has adequate renal function [18].

Denosumab can cause severe symptomatic hypocalcemia, particularly in patients with vitamin D deficiency or renal impairment. The FDA label for Prolia carries a boxed warning for this risk and requires calcium and vitamin D supplementation for all patients unless hypercalcemia is present [1]. Confirming these labs in the PA submission signals to Cigna's reviewing clinician that the prescriber is following the label and may accelerate approval.

DXA re-imaging is typically required at 1 to 2 years to document treatment response and support renewal authorizations. A bone-mineral density increase or stability at the lumbar spine or femoral neck supports the renewal PA; a decline despite adherence strengthens the case for continuation by demonstrating ongoing need [19].

The International Society for Clinical Densitometry recommends DXA every 1 to 2 years during active pharmacotherapy for osteoporosis, with the interval chosen based on baseline severity and expected rate of change [20].

Discontinuing Prolia: The Rebound Fracture Risk Cigna Approvals Should Address

One issue not always reflected in Cigna's standard PA criteria is the clinical risk of stopping denosumab abruptly. Multiple observational studies and post-hoc analyses have shown that discontinuing denosumab without transitioning to a bisphosphonate leads to rapid bone loss and an increased risk of multiple vertebral fractures within 12 to 24 months of the last injection [21].

The Endocrine Society notes this rebound phenomenon specifically: patients who stop denosumab should transition to a bisphosphonate (typically alendronate or zoledronic acid) to preserve the bone-density gains [10]. If Cigna denies a renewal and no bridge therapy is prescribed, the clinical risk to the patient is substantial. This argument can and should be documented in any appeal of a renewal denial: the consequences of stopping denosumab are not comparable to stopping most other osteoporosis drugs, and the appeal letter should cite the published case series on rebound fractures [21].

Prescribers should proactively submit the renewal PA at least 60 days before the patient's next scheduled injection to allow time for appeal if the renewal is denied, and to prevent an unintentional treatment gap.